← Back to Clinical Trials
Recruiting NCT07524387

NCT07524387 Femoral Triangle Block vs Adductor Canal Block on Early Quadriceps Function After Total Knee Arthroplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07524387
Status Recruiting
Phase
Sponsor Social Medical Corporation Daiyukai
Condition Total Knee Arthroplasty
Study Type INTERVENTIONAL
Enrollment 136 participants
Start Date 2026-04-13
Primary Completion 2029-03-15

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Femoral Triangle Block (FTB) GroupAdductor Canal Block (ACB) Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 136 participants in total. It began in 2026-04-13 with a primary completion date of 2029-03-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to compare the effects of femoral triangle block (FTB) and adductor canal block (ACB) on early quadriceps function after total knee arthroplasty (TKA). The main question it aims to answer is whether FTB causes more early quadriceps functional impairment than ACB under a standardized multimodal analgesia protocol. Researchers will compare FTB and ACB using a composite binary functional outcome measured 6 hours after block completion. Quadriceps functional impairment is defined as the inability to perform a structured straight leg raise or quadriceps muscle strength \<50% of the preoperative baseline. Participants will be randomly assigned to receive ultrasound-guided FTB or ACB. All participants will also receive a popliteal plexus block and standardized multimodal analgesia.

Eligibility Criteria

Inclusion Criteria: 1. Adult patients (≥ 20 years of age) are scheduled to undergo primary unilateral TKA. 2. American Society of Anesthesiologists (ASA) physical status I-III. 3. Ability to ambulate independently prior to surgery. 4. Ability to understand the study procedures and provide written informed consent. 5. Planned perioperative anesthesia management including regional anesthesia as part of standard clinical care. 6. Ability to extend the knee below 30 degrees preoperatively (no knee extension contracture) Exclusion Criteria: 1. Known allergy or contraindication to local anesthetic agents used in this study. 2. Pre-existing neurological or neuromuscular disorders affect lower limb strength or motor control. 3. Severe cognitive impairment or psychiatric conditions interfere with study participation or assessment. 4. History of revision knee arthroplasty on the operative side. 5. Severe preoperative quadriceps weakness that precludes reliable baseline strength assessment. 6. Any condition deemed by the investigator to make participation inappropriate.

Contact & Investigator

Central Contact

Norihiro Sakai, MD, PhD

✉ dykmasui@gmail.com

📞 +81-586-72-1211

Principal Investigator

Norihiro Sakai, MD, PhD

PRINCIPAL INVESTIGATOR

Department of Anesthesiology, Daiyukai General Hospital

Frequently Asked Questions

Who can join the NCT07524387 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Total Knee Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07524387 currently recruiting?

Yes, NCT07524387 is actively recruiting participants. Contact the research team at dykmasui@gmail.com for enrollment information.

Where is the NCT07524387 trial being conducted?

This trial is being conducted at Ichinomiya, Japan.

Who is sponsoring the NCT07524387 clinical trial?

NCT07524387 is sponsored by Social Medical Corporation Daiyukai. The principal investigator is Norihiro Sakai, MD, PhD at Department of Anesthesiology, Daiyukai General Hospital. The trial plans to enroll 136 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology